Publications
Detailed Information
Differential Expression of Glut1 in Pulmonary Neuroendocrine Tumors: Correlation with Histological Grade
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Hyun Ju | - |
dc.contributor.author | Yoo, Seol Bong | - |
dc.contributor.author | Lee, Won Woo | - |
dc.contributor.author | Chung, Doo Hyun | - |
dc.contributor.author | Chung, Jin-Haeng | - |
dc.contributor.author | Seo, Jeong-Wook | - |
dc.date.accessioned | 2012-05-31T00:59:03Z | - |
dc.date.available | 2012-05-31T00:59:03Z | - |
dc.date.issued | 2009-06 | - |
dc.identifier.citation | KOREAN JOURNAL OF PATHOLOGY; Vol.43 3; 201-205 | ko_KR |
dc.identifier.issn | 1738-1843 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76640 | - |
dc.description.abstract | Background : Increased glucose uptake, a process that is mediated by glucose transporter (Glut1) proteins, is an important metabolic feature in a variety of cancer cells. The overexpression of Glut1 in human cancers is known to be related to a variety of histopathological parameters, including histological grade, proliferation rate, and lymphatic invasion. The principal objective of this study was to evaluate Glut1 expression in the spectrum of pulmonary neuroendocrine (NE) tumors including typical carcinoid tumor (TC), atypical carcinoid tumor (AC), large cell neuroendocrine carcinoma (LCNEC), and small cell carcinoma (SCC), and to characterize the relationship between Glut1 expression and the histologic grade of NE tumors. Methods : 19 TC, 7 AC, 13 LCNEC, and 6 SCC patients were included in this study. The percentages of Glut1-positive tumor cells in these patients were determined. For statistical analysis, Glut1 expression was subdivided into a Glut1-low expression group (0-30%) and a Glut1-high expression group (31-90%). Results : In our subgroup analyses, the histological grade of pulmonary neuroendocrine (NE) tumors was significantly correlated with Glut1 expression; TC (n=19, 3.6 +/- 4.2%), AC (n=7, 20.0 +/- 4.9%), LCNEC (n=13, 60.0 +/- 21.1%), and SCC (n= 6, 74.2 +/- 16.9%). Glut1-high expression was significantly associated with high-grade NE tumors such as LCNEC and SCC (n=19, 62.6 +/- 21.0%) (p=0.000). Conclusions: The results of this study appear to indicate that Glut1 overexpression is a consistent feature of high-grade NE lung tumors. | ko_KR |
dc.description.sponsorship | This work was supported by grant no 02-2008-029
from the SNUBH Research Fund and partly supported by the Korean Science & Engineering Foundation (KOSEF) through the Tumor Immunity Medical Research Center at Seoul National University College of Medicine. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | KOREAN SOCIETY PATHOLOGISTS | ko_KR |
dc.subject | GLUT1 Protein | ko_KR |
dc.subject | Immunohistochemistry | ko_KR |
dc.subject | Lung neoplasms | ko_KR |
dc.subject | Glucose transporter | ko_KR |
dc.subject | Neuroendocrine tumors | ko_KR |
dc.title | Differential Expression of Glut1 in Pulmonary Neuroendocrine Tumors: Correlation with Histological Grade | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 이현주 | - |
dc.contributor.AlternativeAuthor | 유설봉 | - |
dc.contributor.AlternativeAuthor | 이원우 | - |
dc.contributor.AlternativeAuthor | 정두현 | - |
dc.contributor.AlternativeAuthor | 서정욱 | - |
dc.contributor.AlternativeAuthor | 정진행 | - |
dc.identifier.doi | 10.4132/KoreanJPathol.2009.43.3.201 | - |
dc.citation.journaltitle | KOREAN JOURNAL OF PATHOLOGY | - |
dc.description.citedreference | Song YS, 2008, LUNG CANCER, V61, P54, DOI 10.1016/j.lungcan.2007.11.012 | - |
dc.description.citedreference | Nguyen XC, 2007, EUR J RADIOL, V62, P214, DOI 10.1016/j.ejrad.2006.12.008 | - |
dc.description.citedreference | Khandani AH, 2007, NUCL MED COMMUN, V28, P173 | - |
dc.description.citedreference | Chung JH, 2004, J NUCL MED, V45, P999 | - |
dc.description.citedreference | TRAVIS WD, 2004, WHO INT HISTOLOGICAL | - |
dc.description.citedreference | Kalir T, 2002, CANCER, V94, P1078, DOI 10.1002/cncr.10280 | - |
dc.description.citedreference | Wong CYO, 2001, EUR J NUCL MED, V28, P1702 | - |
dc.description.citedreference | Wang BY, 2000, CANCER, V88, P2774 | - |
dc.description.citedreference | Brown RS, 1999, J NUCL MED, V40, P556 | - |
dc.description.citedreference | Ito T, 1998, MODERN PATHOL, V11, P437 | - |
dc.description.citedreference | Travis WD, 1998, HUM PATHOL, V29, P272 | - |
dc.description.citedreference | Baer SC, 1997, J AM ACAD DERMATOL, V37, P575 | - |
dc.description.citedreference | Younes M, 1997, CANCER, V80, P1046 | - |
dc.description.citedreference | Voldstedlund M, 1997, APMIS, V105, P537 | - |
dc.description.citedreference | Haber RS, 1997, THYROID, V7, P363 | - |
dc.description.citedreference | Younes M, 1997, CANCER EPIDEM BIOMAR, V6, P303 | - |
dc.description.citedreference | Younes M, 1996, CLIN CANCER RES, V2, P1151 | - |
dc.description.citedreference | Younes M, 1996, CANCER RES, V56, P1164 | - |
dc.description.citedreference | Younes M, 1995, ANTICANCER RES, V15, P2895 | - |
dc.description.citedreference | NAGASE Y, 1995, J UROLOGY, V153, P798 | - |
dc.description.citedreference | MELLANEN P, 1994, INT J CANCER, V56, P622 | - |
dc.description.citedreference | BROWN RS, 1993, CANCER, V72, P2979 | - |
dc.description.citedreference | TAKATA K, 1992, CELL TISSUE RES, V267, P407 | - |
dc.description.citedreference | PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911 | - |
dc.description.citedreference | PARDRIDGE WM, 1990, J BIOL CHEM, V265, P18035 | - |
dc.description.citedreference | ISSELBAC.KJ, 1972, NEW ENGL J MED, V286, P929 | - |
dc.description.tc | 0 | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.